quant Healthcare Fund - Growth Option - Regular Plan
₹16.2694
₹0.05 (-0.29%)
NAV as of 29 May 2026
Today's NAV — all variants
Regular · Growth
₹₹16.2694
₹0.05 (-0.29%)
29 May 2026
AMFI: 151855
Direct · Growth
₹₹17.0489
₹0.05 (-0.28%)
29 May 2026
AMFI: 151853
Regular · IDCW
₹₹16.2685
₹0.05 (-0.29%)
29 May 2026
AMFI: 151856
Direct · IDCW
₹₹17.0473
₹0.05 (-0.28%)
29 May 2026
AMFI: 151854
Returns (Lumpsum)
CAGR for periods ≥ 1 yearSIP Returns (XIRR)
₹1,000/month SIP, annualisedSIP since inception — what ₹500/month became
Real NAV backtest from day one
₹17,000
Invested
₹19,744
Value today
10.6%
XIRR (p.a.)
₹500/month SIP from fund inception · Current value as of today
Try SIP Calculator with this fund's history₹1,000 lumpsum at launch — value today
Invested on the fund's first NAV date
₹1,000
Invested
₹1,627
Value today
18.5%
CAGR (p.a.)
One-time investment at fund inception · Growth purely from NAV appreciation
Try Lumpsum Calculator₹6L corpus via 12-month STP from a liquid fund at inception
₹50K/month transferred from HDFC Liquid → this fund at launch
₹6,00,000
Invested
₹8,23,976
Value today
-15.6%
vs lumpsum
Direct lumpsum would have beaten STP by 15.6% — but STP reduced timing risk
Model your own STP with real NAVBeat the benchmark — ₹500/month SIP
Same SIP in this fund vs the benchmark index
This fund
₹19,744
Benchmark
₹18,325
+₹1,419 extra wealth vs the benchmark index
Backtest this SIP yourselfDirect vs Regular — ₹500/month over 2 years
Expense ratio drag on your actual returns
Direct plan
₹13,695
Regular plan
₹13,460
Direct earns ₹235 more on a ₹12K investment — 0.98% extra return per year
Same fund, same NAV history — only the expense ratio differs. Direct plans always outperform Regular over time.
Learn about Direct vs Regular plansFund Details
Risk Metrics
Trailing 1 year, annualised-0.21
Sharpe Ratio
-0.01
Alpha
0.45
Beta
-0.20
Sortino
17.89%
Std Dev
-20.07%
Max Drawdown
Portfolio Holdings
Top 24 holdings · as of Apr 2026
| Security | % NAV |
|---|---|
Zydus Wellness Ltd INE768C01028 | 9.27% |
ANTHEM BIOSCIENCES LIMITED INE0CZ201020 | 9.17% |
Aster DM Healthcare Limited INE914M01019 | 8.90% |
SMS Pharmaceuticals Limited INE812G01025 | 8.86% |
Sequent Scientific Limited INE807F01027 | 8.62% |
Alivus Life Sciences INE03Q201024 | 7.27% |
HFCL Limited INE548A01028 | 7.14% |
Pfizer Ltd INE182A01018 | 6.42% |
Aurobindo Pharma Limited INE406A01037 | 5.15% |
ICICI Prudential Life Insurance Co Ltd INE726G01019 | 4.35% |
HDFC Life Insurance Co Ltd INE795G01014 | 3.80% |
Medplus Health Services Limited INE804L01022 | 3.72% |
Glaxosmithkline Pharmaceuticals Ltd INE159A01016 | 2.16% |
Gland Pharma Limited INE068V01023 | 1.40% |
Strides Pharma Science Ltd INE939A01011 | 0.30% |
| Security | % NAV |
|---|---|
91 Days Treasury Bill 22-May-2026 IN002025X463 | 1.70% |
91 Days Treasury Bill 07-May-2026 IN002025X448 | 0.85% |
91 Days Treasury Bill 14-May-2026 IN002025X455 | 0.85% |
91 Days Treasury Bill 04-Jun-2026 IN002025X489 | 0.85% |
91 Days Treasury Bill 16-Jul-2026 IN002026X024 | 0.84% |
91 Days Treasury Bill 23-Jul-2026 IN002026X032 | 0.84% |
| Security | % NAV |
|---|---|
ICICI Bank Limited 26/05/2026 ICICIBANK260526 | 1.34% |
HDFC Life Insurance Co Ltd 26/05/2026 HDFCLIFE260526 | 1.11% |
| Security | % NAV |
|---|---|
NCA-NET CURRENT ASSETS | -2.40% |
Performance Comparison
Interested in This Fund?
Our experts will help you decide if this fund fits your goals.
Compare with Similar Funds
Investment Objective
quant Healthcare Fund - Growth Option - Regular Plan invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
quant Healthcare Fund - Growth Option - Regular Plan is a Sectoral / Thematic mutual fund offered by quant Mutual Fund. The fund has been operational for over 2 years. It manages assets worth ₹344 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against NIFTY HEALTHCARE INDEX TRI. The current expense ratio is 2.42%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations